Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Phosphoric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC34A1 | Q06495 | 1/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 2/20 | 0.35 |
| ▸ | CA4 | P22748 | 2/20 | 0.35 |
| ▸ | CA5A | P35218 | 2/20 | 0.35 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.35 |
| ▸ | MMP2 | P08253 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | FDPS | P14324 | 1/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phosphoric Acid SCHEMBL23091295 | 1.00 | SLC34A1 (0.67) | SLC34A1KDM4ECYP2C19KMT2ALMNA | |
| Phosphoric Acid SCHEMBL28498921 | 1.00 | SLC34A1 (0.67) | SLC34A1KDM4ECYP2C19KMT2ALMNA | |
| Phosphoric Acid SCHEMBL6692776 | 1.00 | SLC34A1 (0.67) | SLC34A1KDM4ECYP2C19KMT2ALMNA | |
| Phosphoric Acid SCHEMBL28373362 | 1.00 | SLC34A1 (0.67) | SLC34A1KDM4ECYP2C19KMT2ALMNA | |
| Phosphoric Acid SCHEMBL30341783 | 1.00 | SLC34A1 (0.67) | SLC34A1KDM4ECYP2C19KMT2ALMNA | |
| Phosphoric Acid SCHEMBL3178457 | 0.95 | SLC34A1 (0.58) | SLC34A1KDM4ECYP2C19KMT2ALMNA | |
| Phosphoric Acid SCHEMBL653726 | 0.95 | SLC34A1 (0.73) | SLC34A1KDM4ECYP2C19KMT2ALMNA | |
| Phosphoric Acid SCHEMBL737699 | 0.95 | SLC34A1 (0.58) | SLC34A1KDM4ECYP2C19KMT2ALMNA | |
| Phosphoric Acid SCHEMBL101070 | 0.95 | — | — | |
| Phosphoric Acid SCHEMBL8972786 | 0.95 | SLC34A1 (0.73) | SLC34A1KDM4ECYP2C19KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240158792-A1 | Composition Comprising Antisense Oligonucleotide and Use Thereof for Treatment of Duchenne Muscular Dystrophy | NIPPON SHINYAKU CO., LTD. (JP) | 2024-05-16 | — | — | US | disclosed |
| EP-3815696-A1 | COMPOSITION COMPRISING ANTISENSE OLIGONUCLEOTIDE AND USE THEREOF FOR TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | Nippon Shinyaku Co., Ltd. (JP) | 2021-05-05 | — | — | EP | disclosed |
| CN-112399849-A | Compositions comprising antisense oligonucleotides and their use in the treatment of duchenne muscular dystrophy | 日本新药株式会社 | 2021-02-23 | — | — | CN | disclosed |
| CN-104819888-B | A kind of ELISA sample diluting liquids and preparation method thereof | 中国农业科学院兰州兽医研究所 | 2018-01-09 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240158792-A1 | Composition Comprising Antisense Oligonucleotide and Use Thereof for Treatment of Duchenne Muscular Dystrophy | MTPN, UTRN, SMN1; SMN2 | SLC34A1 1057/4885KDM4E 3242/4885CYP2C19 4727/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.